OptimizeRx prelim Q1 revenue $18.5-19.2M (+40% YoY); ahead of consensus

OptimizeRx Corp

2024-Q1 EPS reported -$0.38 revenue$19,690,000

Revenue expected between $18.5M and $19.2M for Q1 2024, over 40% growth YoY; GAAP net loss $(8.2)-$(7.0)M.
Adjusted EBITDA loss of $(1.0)-$(0.7)M; results driven by DAAP platform and October 2023 Medicx acquisition.
Signed 9 new Dynamic Audience Activation Platform (DAAP) deals in Q1; cross-selling ahead of internal expectations.
Medicx integration ahead of schedule; management estimates $2.8B potential opportunity from existing brands alone.
Earnings call scheduled for May 14, 2024 at 4:30 p.m. ET to discuss full Q1 results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OptimizeRx Corp reported first quarter for the period ended March 31, 2024 results: revenue between $18.5 million and $19.2 million.

Period: first quarter for the period ended March 31, 2024
Revenue: between $18.5 million and $19.2 million
Result: preliminary results

Exact text from the filing

the Company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss and Adjusted EBITDA loss between $(8.2) - $(7.0) million and $(1.0) - $(0.7) million, respectively

View on SEC.gov

292 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-037205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.